Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MESO message board posts where the ticker symbol MESO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

Related news from
Mon, 26 Nov 2018
11:00:00 +0000
Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China
NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering.
Thu, 15 Nov 2018
21:33:41 +0000
Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights
MELBOURNE, Australia and NEW YORK, Nov. 15, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided operational highlights for the.
Thu, 15 Nov 2018
11:00:00 +0000
Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018
NEW YORK and MELBOURNE, Australia, Nov. 15, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended September 30, 2018 in a.
Mon, 12 Nov 2018
00:59:51 +0000
Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval
NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from a 159-patient randomized, sham-controlled Phase 2.
Fri, 09 Nov 2018
11:00:00 +0000
Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions
NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its.
Wed, 24 Oct 2018
10:05:00 +0000
Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa
Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan for wound healing in patients with Epidermolysis Bullosa (EB). JCR has received Orphan Designation for the allogeneic mesenchymal stem cell (MSC) product TEMCELL HS Inj1 in the treatment of EB. Based on promising results from an investigator-initiated trial in Japan, JCR intends to seek label extension for TEMCELL in Japan beyond its existing approval for the treatment of acute graft versus host disease.
Mon, 22 Oct 2018
12:25:00 +0000
Investor Expectations to Drive Momentum within ChannelAdvisor, WideOpenWest, Arcos Dorados, Mesoblast, Ferrari N.V, and Weatherford International — Discovering Underlying Factors of Influence
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Fri, 12 Oct 2018
10:00:00 +0000
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China
Mesoblast has received US$40 million (AUD$57 million) from Tasly, comprising an upfront technology access fee of US$20 million and an equity purchase of US$20 million for which Mesoblast Limited has issued 14,464,259 fully paid ordinary shares to Tasly. As consideration, Tasly has received exclusive rights and will fund all development, manufacturing and commercialization activities in China for MPC-150-IM for the treatment and prevention of chronic heart failure and MPC-25-IC for the prevention and treatment of acute myocardial infarction.
Tue, 09 Oct 2018
16:00:00 +0000
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first.
Tue, 02 Oct 2018
10:00:00 +0000
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial.
Fri, 28 Sep 2018
14:06:02 +0000
3 Biotech Stocks With Rising Estimates in the Past Month
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Thu, 20 Sep 2018
10:30:00 +0000
Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast’s Phase 3 Trial for Acute Graft Versus Host Disease
NEW YORK and MELBOURNE, Australia, Sept. 20, 2018-- Mesoblast Limited today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease ...
Thu, 30 Aug 2018
20:50:53 +0000
Mesoblast Limited (ASX:MSB) Is Expected To Breakeven
Mesoblast Limited’s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.8m and a trailing-twelve month of -US$41.6m, the AU$750.5m market-cap alleviates its loss by movingRead More...
Wed, 29 Aug 2018
11:43:07 +0000
Mesoblast's Earnings Outlook
Mesoblast (NASDAQ: MESO ) releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Mesoblast's Q4 earnings report. Earnings and Revenue Analysts are predicting Mesoblast will ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is a site for sharing information about the atypical investments that the majority of investors have not discovered. It is about finding the next value/growth sector/investment before all the major houses on the Street are recommending it." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards